Hepatitis E seroprevalence in the Americas: A systematic review and meta‐analysis

Background & Aims While hepatitis E virus infections are a relevant topic in Europe, knowledge about epidemiology of hepatitis E virus infections in the USA and Latin America is still limited. Aim of this study was to estimate anti‐hepatitis E virus IgG seroprevalence in the Americas and to assess whether low socioeconomic status is associated with hepatitis E virus exposure. Methods We performed a systematic review and meta‐analysis. Literature search was performed in PubMed for articles published 01/1994‐12/2016. Prevalence was estimated using a mixed‐effects model and reported in line with PRISMA reporting guidelines. Results Seroprevalence was significantly higher in the USA than in Latin America, independently of assay, patient cohort, methodological quality or study year (OR: 1.82 (1.06‐3.08), P = .03). Patients in the USA had a more than doubled estimated seroprevalence (up to 9%, confidence interval 5%‐15.6%) than those in Brazil (up to 4.2%, confidence interval 2.4%‐7.1%; OR: 2.27 (1.25‐4.13); P = .007) and Mixed Caribbean (up to 1%, OR: 8.33 (1.15‐81.61); P = .04). A comparison with published data from Europe demonstrated that anti‐hepatitis E virus seroprevalence in the USA and Europe did not differ significantly (OR: 1.33 (0.81‐2.19), P = .25), while rate in South America was significantly lower than that in Europe (OR: 0.67 (0.45‐0.98), P = .04). Conclusions Hepatitis E virus is common in the USA. Surprisingly, the risk of hepatitis E virus exposure was low in many South American countries. Seroprevalence did not differ significantly between Europe and the USA. Hence, hepatitis E virus is not limited to countries with low sanitary standards, and a higher socioeconomic status does not protect populations from hepatitis E virus exposure.